Donafenib

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC

TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension

Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma

Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors

Donafenib for Previously Treated Metastatic Colorectal Cancer

HAIC Combined With Toripalimab and Donafenib for Advanced BTC

HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC